Avadim Health postpones $75 million IPO
Avadim Health, which develops and sells non-prescription topical antiseptics and analgesics under the Theraworx brand, postponed its IPO on Thursday. It had filed to raise $75 million by offering 5 million shares at a price range of $14 to $16.
The Asheville, NC-based company was founded in 2007 and booked $44 million in sales for the 12 months ended September 30, 2019. It had planned to list on the Nasdaq under the symbol AHI. Raymond James, SunTrust Robinson Humphrey and Oppenheimer & Co. were set to be the joint bookrunners on the deal.
Investment Disclosure: Renaissance IPO ETF (symbol: IPO) Renaissance International ETF (symbol: IPOS)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- Waste management company GFL Environmental relaunches IPO with lowered range of $20 to $21; adds $700 million equity unit offering
- Gene therapy developer Passage Bio prices upsized IPO at the $18 high end
- High-growth medical device maker Inari Medical files for a $100 million IPO
- Preclinical biotech Passage Bio increases IPO share offering by 35%, now plans to raise $170 million